Literature DB >> 2252523

Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes.

R M Termaat1, K Brinkman, F van Gompel, L P van den Heuvel, J H Veerkamp, R J Smeenk, J H Berden.   

Abstract

To study in more detail the cross-reactive binding of anti-DNA antibodies to heparan sulfate (HS) and heparan sulfate proteoglycan (HSPG) purified from glomerular basement membranes (GBM), the binding pattern of 31 murine IgG anti-DNA MoAbs, derived from MRL/lpr, NZB/W and graft-versus-host diseased mice, was analysed. In ELISA we found binding of 10 anti-DNA MoAbs to HS. Seven of the 10 anti-HS positive clones bound to HSPG but not to the HSPG core protein in ELISA and/or on Western blots. However, DNase-I treatment partly reduced this binding, whereas after purification of MoAb by protein-A sepharose chromatography under dissociative conditions, all clones completely lost their binding capacity to HS and HSPG. Culturing of hybridoma cells in the presence of 3H-thymidine revealed DNA bound to the MoAb. Although the binding to HS and HSPG could be reconstituted by the addition of the protein-A column effluent, this was not possible by the addition of DNA alone. Therefore, we performed immunoprecipitation of the effluent with purified MoAb and subsequent SDS-PAGE which showed that the complex also contained histones. However, histones alone were also not able to reconstitute the binding to HS and HSPG. It is concluded that binding of anti-DNA MoAb to HS and GMB-HSPG is mediated via bound complexes containing both DNA and histones. A comparable reaction with polyclonal anti-DNA Ab might play a role in the pathogenesis of SLE nephritis, since histones have a very high affinity for HS, the major glycosaminoglycan of the GBM.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252523     DOI: 10.1016/s0896-8411(05)80019-8

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  24 in total

1.  Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.

Authors:  Quan-Zhen Li; Quan Li Zhen; Chun Xie; Tianfu Wu; Meggan Mackay; Cynthia Aranow; Chaim Putterman; Chandra Mohan
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus.

Authors:  G Q Shen; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Idiotype usage by polyclonally activated B cells in experimental autoimmunity and infection.

Authors:  M Sutmuller; J J Baelde; M P Madaio; J A Bruijn; E De Heer
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

4.  Predominant role for activation-induced cytidine deaminase in generating IgG anti-nucleosomal antibodies of murine SLE.

Authors:  Thiago Detanico; Wenzhong Guo; Lawrence J Wysocki
Journal:  J Autoimmun       Date:  2015-01-26       Impact factor: 7.094

5.  Anti-subnucleosome reactivities in systemic lupus erythematosus (SLE) patients and their first-degree relatives.

Authors:  C Mohan; F Liu; C Xie; R C Williams
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 6.  Anti-DNA antibodies. Their idiotypes and SLE.

Authors:  D Buskila; Y Shoenfeld
Journal:  Clin Rev Allergy       Date:  1994

7.  Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations.

Authors:  R M Termaat; K Brinkman; J C Nossent; A J Swaak; R J Smeenk; J H Berden
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

8.  Higher anti-heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis.

Authors:  C Kramers; R M Termaat; E J ter Borg; M C van Bruggen; C G Kallenberg; J H Berden
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  Detection of antibodies to DNA: a technical assessment.

Authors:  R Smeenk; M Hylkema
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

Review 10.  Anti-dsDNA: choice of assay in relation to clinical value.

Authors:  R J Smeenk; H G van den Brink; K Brinkman; R M Termaat; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.